|PET imaging for β-amyloid and tau|
: 311 : 2015.03.23 13:32
|일시 : 2015.03.25 17:00|
|소속 : Gangnam Severance Hospital, Yonsei University College of Medicine|
|발표자 : 류철형|
|장소 : R404|
The prototypical radiotracer 11C-PIB is highly specific for β-amyloid and clearly shows the amyloid pathology in good correlation with the accumulation of cortical amyloid. Two thirds of mild cognitive impairment (MCI) patients show PIB positivity and 60% of them progress to clinical Alzheimer’s disease (AD) in 2 years. In healthy elderly, β-amyloid deposition may be almost inevitable, and the prevalence of PIB positivity approximates the prevalence of plaques. PIB positivity precedes the functional and anatomical deterioration in FDG PET and MR, and can be a good biomarker for diagnosing preclinical AD. Four 18F-labelled radiotracers are ready to be used in clinical purpose, and until now 18F-AZD4694 is known to be the best 18F-labelled radiotracer which can replicate the binding characteristics of 11C-PIB. 18F-florbetaben will be clinically available in 2015 in Korea.
Several tau-specific radiotracers were already developed. According to the published reports and abstracts, 18F-T807, a commercial radiotracer for tau, and 11C-PBB3 are currently most promising 18F-labelled radiotracers which bind to tau protein in non-AD tauopathies as well as in AD.